ChinaNationalAccordMedicinesCorporationLtd.
TheThirdQuarterlyReportfor2020
October2020
SectionI.ImportantNotice
BoardofDirectors,SupervisoryCommittee,alldirectors,supervisorsandseniorexecutivesofChinaNationalAccordMedicinesCorporationLtd.(hereinafterreferredtoastheCompany)herebyconfirmthattherearenoanyfictitiousstatements,misleadingstatements,orimportantomissionscarriedinthisreport,andshalltakeallresponsibilities,individualand/orjoint,forthereality,accuracyandcompletionofthewholecontents.AlldirectorsarepresentthemeetingoftheBoardfordeliberatingtheThirdQuarterReportoftheCompanyinperson.LinZhaoxiong,personinchargeoftheCompany,headoftheaccountingworksGuGuolinandWangYing,accountingbodyprincipals(accountantincharge)herebyconfirmthattheFinancialReportoftheThirdQuarterlyReportisauthentic,accurateandcomplete.
SectionII.BasicinformationofCompanyI.MainaccountingdataandindexWhetherithasretroactiveadjustmentorre-statementonpreviousaccountingdataornot
√Yes□NoCauseofretroactiveadjustmentorrestatementEnterprisescombinedunderthesamecontrol
| Currentperiod-end | Period-endoflastyear | Increase/decrease | ||||||
| Beforeadjustment | Afteradjustment | Afteradjustment | ||||||
| Totalassets(RMB) | 42,013,200,732.51 | 33,520,609,123.67 | 34,028,843,214.20 | 23.46% | ||||
| Netassetsattributabletoshareholdersoflistedcompany(RMB) | 13,554,151,733.76 | 12,806,410,865.92 | 12,911,140,435.88 | 4.98% | ||||
| Currentperiod | Sameperiodoflastyear | Increase/decreaseincomparisonwithsameperiodoflastyear | Year-begintoendofthePeriod | Sameperiodoflastyear | Increase/decreaseincomparisonwithyear-begintoperiod-endoflastyear | |||
| Beforeadjustment | Afteradjustment | Afteradjustment | Beforeadjustment | Afteradjustment | Afteradjustment | |||
| Operatingrevenue(RMB) | 15,710,564,937.11 | 13,647,793,431.64 | 13,824,236,956.99 | 13.65% | 42,880,505,125.63 | 38,875,940,809.07 | 39,423,435,772.29 | 8.77% |
| Netprofitattributabletoshareholdersofthelistedcompany(RMB) | 354,134,165.83 | 311,310,706.52 | 310,253,592.48 | 14.14% | 997,585,746.42 | 962,144,066.92 | 959,408,007.03 | 3.98% |
| Netprofitattributabletoshareholdersofthelistedcompanyafterdeductingnon-recurringgainsandlosses(RMB) | 354,311,453.14 | 303,365,280.52 | 303,365,280.52 | 16.79% | 981,328,472.59 | 943,065,728.47 | 943,065,728.47 | 4.06% |
| Netcashflowarisingfromoperatingactivities(RMB) | 545,143,142.89 | -90,795,420.13 | -80,360,840.58 | 778.37% | 1,983,347,186.24 | 1,072,962,161.22 | 1,058,793,280.31 | 87.32% |
| Basicearningspershare | 0.83 | 0.74 | 0.72 | 15.28% | 2.33 | 2.25 | 2.24 | 4.02% |
| (RMB/Share) | ||||||||
| Dilutedearningspershare(RMB/Share) | 0.83 | 0.74 | 0.72 | 15.28% | 2.33 | 2.25 | 2.24 | 4.02% |
| WeightedaverageROE | 2.65% | 2.53% | 2.50% | 0.15percentagepointsup | 7.56% | 7.94% | 7.85% | 0.29percentagepointsdecline |
Itemsandamountofextraordinaryprofit(gains)/losses
√Applicable□Notapplicable
InRMB
| Item | Amountfromyear-begintoendofthePeriod | Note |
| Gains/lossesfromthedisposalofnon-currentasset(includingthewrite-offthataccruedforimpairmentofassets) | 6,670,438.32 | Mainlyfortheincomefromoff-leasestores. |
| Governmentalsubsidyreckonedintocurrentgains/losses(notincludingthesubsidyenjoyedinquotaorrationaccordingtonationalstandards,whicharecloselyrelevanttoenterprise’sbusiness) | 36,307,932.91 | MainlyaffectedbytheCOVID-19,allkindsofspecialsubsidiesreceivedintheperiodandtaxreduction&exemption. |
| Reversalofimpairmentreserveforaccountreceivablewithseparateimpairmenttesting | 378,494.91 | |
| Consigningfeereceivedforconsignedoperation | 961,488.75 | |
| Othernon-operatingincomeandexpenditureexceptfortheaforementioneditems | -11,989,346.42 | |
| Gains/lossesitemsqualifieddefinitionofthenon-recurringgains/losses | 955,958.26 | |
| Less:impactonincometax | 7,360,561.86 | |
| Impactonminorityshareholders’equity(post-tax) | 9,667,131.04 | |
| Total | 16,257,273.83 | -- |
Concerningtheextraordinaryprofit(gain)/lossdefinedbyQ&AAnnouncementNo.1onInformationDisclosureforCompaniesOfferingTheirSecuritiestothePublic---ExtraordinaryProfit/loss,andtheitemsdefinedasrecurringprofit(gain)/lossaccordingtothelistsofextraordinaryprofit(gain)/lossinQ&AAnnouncementNo.1onInformationDisclosureforCompaniesOfferingTheirSecuritiestothePublic---ExtraordinaryProfit/loss,explainreasons
□Applicable√NotapplicableInreportingperiod,theCompanyhasnoparticularaboutitemsdefinedasrecurringprofit(gain)/lossaccordingtothelistsofextraordinaryprofit(gain)/lossinQ&AAnnouncementNo.1onInformationDisclosureforCompaniesOfferingTheirSecuritiestothePublic---ExtraordinaryProfit/loss.
II.Statementofthetotalshareholdersandshares-heldoftoptenshareholdersatendofthePeriod
1.Totalnumberofcommonshareholdersattheendofthisreportperiodandtoptencommonshareholders
InShare
| Totalcommonshareholdersattheendofreportperiod | 34,927 | Totalpreferenceshareholderswithvotingrightsrecoveredatendofreportingperiod(ifapplicable) | 0 | |||||
| Toptenshareholders | ||||||||
| Shareholders | Natureofshareholder | Proportionofsharesheld | Amountofsharesheld | Amountofrestrictedsharesheld | Numberofsharepledged/frozen | |||
| Stateofshare | Amount | |||||||
| SinopharmGroupCo.,Ltd. | State-ownedcorporate | 56.06% | 239,999,991 | 5,505,770 | ||||
| FIRSTSENTIERINVESTORSGLOBALUMBRELLAFUNDPLC-FSSACHINAGROWTHFUND | Overseascorporate | 2.68% | 11,469,644 | |||||
| ShanghaiGaoyiAssetManagementPartnership(LimitedPartnership)-GaoyiLinshanNo.1YuanwangFund | Domesticnonstate-ownedcorporate | 2.34% | 10,000,000 | |||||
| HongKongSecuritiesClearingCompanyLtd. | Overseascorporate | 2.15% | 9,199,504 | |||||
| NationalSocialSecurityFund118Portfolio | Domesticnonstate-ownedcorporate | 1.59% | 6,791,699 | |||||
| ChinaNationalPharmaceuticalForeignTrade | State-ownedcorporate | 1.24% | 5,323,043 | |||||
| Corp. | ||||||
| CentralHuijinInvestmentLtd. | State-ownedcorporate | 0.89% | 3,804,400 | |||
| IndustrialandCommercialBankofChina-GuangfaSteadyGrowthSecuritiesInvestmentFund | Domesticnonstate-ownedcorporate | 0.89% | 3,802,617 | |||
| BBHBOSS/AFIDELITYFD-CHINAFOCUSFD | Overseascorporate | 0.78% | 3,358,761 | |||
| NationalSocialSecurityFund115Portfolio | Domesticnonstate-ownedcorporate | 0.78% | 3,333,913 | |||
| Particularabouttoptenshareholderswithun-restrictsharesheld | ||||||
| Shareholders | Amountofun-restrictsharesheld | Typeofshares | ||||
| Type | Amount | |||||
| SinopharmGroupCo.,Ltd. | 234,494,221 | RMBordinaryshares | 234,494,221 | |||
| FIRSTSENTIERINVESTORSGLOBALUMBRELLAFUNDPLC-FSSACHINAGROWTHFUND | 11,469,644 | Domesticallylistedforeignshares | 11,469,644 | |||
| ShanghaiGaoyiAssetManagementPartnership(LimitedPartnership)-GaoyiLinshanNo.1YuanwangFund | 10,000,000 | RMBordinaryshares | 10,000,000 | |||
| HongKongSecuritiesClearingCompanyLtd. | 9,199,504 | RMBordinaryshares | 9,199,504 | |||
| NationalSocialSecurityFund118Portfolio | 6,791,699 | RMBordinaryshares | 6,791,699 | |||
| ChinaNationalPharmaceuticalForeignTradeCorp. | 5,323,043 | RMBordinaryshares | 5,323,043 | |||
| CentralHuijinInvestmentLtd. | 3,804,400 | RMBordinaryshares | 3,804,400 | |||
| IndustrialandCommercialBankofChina-GuangfaSteadyGrowthSecuritiesInvestmentFund | 3,802,617 | RMBordinaryshares | 3,802,617 | |||
| BBHBOSS/AFIDELITYFD-CHINAFOCUSFD | 3,358,761 | Domesticallylistedforeignshares | 3,358,761 |
| NationalSocialSecurityFund115Portfolio | 3,333,913 | RMBordinaryshares | 3,333,913 |
| Explanationonassociatedrelationshipamongtheaforesaidshareholders | SinopharmGroupCo.,Ltd.andChinaNationalPharmaceuticalForeignTradeCorporationhavethesameactualcontroller,whichisChinaNationalPharmaceuticalGroupCorporation.ItisunknownthatthereexistsnoassociatedrelationshiporbelongstotheconsistentactionistamongtheothertradableshareholdersregulatedbytheManagementMeasureofInformationDisclosureonChangeofShareholdingforListedCompanies. | ||
Whethertoptencommonshareholdersortoptencommonshareholderswithun-restrictsharesheldhaveabuy-backagreementdealinginreportingperiod
□Yes√NoTheshareholdersoftheCompanyhavenobuy-backagreementdealinginreportingperiod.
2.Totalofshareholderswithpreferredstockheldandthetoptenshareholdings
□Applicable√Notapplicable
SectionIII.ImportanteventsI.Particularaboutmajorchangesfromitemsofmainaccountingstatementsandfinancialindexesaswellasreasons
√Applicable□Notapplicable
1.Notesreceivablehadadecreaseof276.5989millionyuanfromthebeginningoftheperiod,withagrowthrateof-34.87%,mainlyduetochangesintheprocurementmodeofhospitalcustomersandchangesinsettlementmethodscausedbytheGPOpolicy;
2.Accountsreceivablehadanincreaseof5,446.291millionyuanfromthebeginningoftheperiod,withagrowthrateof50.84%,mainlyduetotheincreaseindaysofturnoverofaccountsreceivablecausedbyimpactoftheCOVID-19outbreakandmarketenvironment,andalsotheincreaseinaccountsreceivableattheendoftheperiodbroughtaboutbythenewlymergedcompany;
3.Receivablefinancinghadanincreaseof168.1186millionyuanfromthebeginningoftheperiod,withagrowthrateof37.67%,mainlyduetochangesinsettlementmethodswithcustomersandtheincreaseinfinancingofaccountsreceivableattheendoftheperiodbroughtaboutbythenewlymergedcompany;
4.Advancestosuppliershadanincreaseof138.3328millionyuanfromthebeginningoftheperiod,withagrowthrateof35.49%,mainlyduetotheincreaseinprepaymentsastheimportlettersofcreditexpired;
5.Dividendreceivablehadadecreaseof0.8349millionyuanfromthebeginningoftheperiod,withagrowthrateof-100%,mainlybecauseShanghaiDingqunEnterpriseManagementConsultingCo.,Ltd.hasbeenincludedinthescopeofconsolidationinthecurrentperiod,forthedividendsreceivableofthesameperiodlastyear,thereisnomorebalanceattheconsolidationlevelafterinternaloffset;
6.Othercurrentassetshadadecreaseof32.7243millionyuanfromthebeginningoftheperiod,withagrowthrateof-32.02%,mainlyduetothedecreaseintheinputtaxtobedeductedforvalue-addedtax;
7.Intangibleassetshadanincreaseof373.8836millionyuanfromthebeginningoftheperiod,withagrowthrateof99.76%,mainlyduetothesalesnetworkgeneratedbytheacquisitionofShanghaiDingqunEnterpriseManagementConsultingCo.,Ltd.bythesubsidiaryGuodaDrugStoreinthecurrentperiod;
8.Goodwillhadanincreaseof1,736.49millionyuanfromthebeginningoftheperiod,withagrowthrateof
171.92%,mainlyduetotheacquisitionofChengdaFangyuanPharmaceuticalGroupCo.,Ltd.andShanghaiDingqunEnterpriseManagementConsultingCo.,Ltd.bythesubsidiaryGuodaDrugStoreinthecurrentperiod;
9.Deferredtaxassetshadanincreaseof35.4016millionyuanfromthebeginningoftheperiod,withagrowthrateof56.09%,mainlyduetotheincreaseintheendingbalancebroughtaboutbythenewlymergedcompaniesinthecurrentperiod;
10.Othernon-currentassetshadanincreaseof195.5173millionyuanfromthebeginningoftheperiod,withagrowthrateof252.75%,mainlyduetotheprocurementofemergencyspecialreservematerialsforthepreventionandcontroloftheCOVID-19outbreakattherequestofthegovernment;
11.Short-termborrowingshadanincreaseof1,770.8543millionyuanfromthebeginningoftheperiod,withagrowthrateof121.87%,mainlyduetotheincreaseinsupplychainfinancinginthecurrentperiodandtheincreaseintheendingshort-termloansbroughtaboutbythenewlymergedcompanies;
12.Accountspayablehadanincreaseof3,488.0446millionfromthebeginningoftheperiod,withagrowthrateof52.03%,mainlybecausethenumberofdaysforsettlementofaccountspayablehasincreasedduetotheimpactoftheCOVID-19outbreak,andtheendingaccountspayablebroughtaboutbythenewlymergedcompanieshaveincreased;
13.Interestpayablehadadecreaseof9.5779millionyuanfromthebeginningoftheperiod,withagrowthrateof-40.53%,mainlyduetothescheduledpaymentoffactoringinterestonaccountsreceivable;
14.Long-termborrowingshadanincreaseof31.6338millionyuanfromthebeginningoftheperiod,withagrowthrateof100.00%,mainlyduetotheloanreceivedfromSinopharmFinanceCompanyentrustedbyChinaNationalPharmaceuticalGroupCorporationintheperiod;
15.Long-termpayablehadanincreaseof6.1382millionyuanfromthebeginningoftheperiod,withagrowthrateof767.27%,mainlyduetotheincreaseintheendingbalancebroughtaboutbythenewlymergedcompaniesinthecurrentperiod;
16.Provisionshadanincreaseof67.7774millionyuanfromthebeginningoftheperiod,withagrowthrateof
100.00%,mainlyduetotheincreaseoftheendingbalancecausedbynewenterpriseincorporatedincurrentperiod;
17.Deferredtaxliabilitieshadanincreaseof90.3191millionyuanfromthebeginningoftheperiod,withagrowthrateof76.36%,mainlyduetotheacquisitionofShanghaiDingqunEnterpriseManagementConsultingCo.,Ltd.bythesubsidiaryGuodaDrugStoreinthecurrentperiod,resultingindeferredincometaxliabilitiesrecognizedbytheassetfairassessmentandappreciation；
18.Othernon-currentliabilitieshadanincreaseof463.1607millionyuanfromthebeginningoftheperiod,withagrowthrateof632.25%,mainlyduetotheadvancepurchaseofgovernmentemergencyreservematerialsforthe
preventionandcontroloftheCOVID-19outbreak;
19.Otherincomeshadayear-on-yearincreaseof17.58millionyuan,withagrowthrateof61.45%,mainlybecausevariousspecialsubsidiesandtaxreductionsreceivedinthisperiodhaveincreasedduetotheimpactoftheCOVID-19outbreak;
20.Creditimpairmentlosseshadayear-on-yearincreaseof14.4377millionyuan,withagrowthrateof98.58%,mainlyduetotheexpansionofsalesvolume,theincreaseinendingaccountsreceivablecomparedwiththesameperiodlastyear,andthenumberofdaysofaccountsreceivableturnoverhasincreasedduetotheimpactofthenewcrownpneumoniaepidemic,sotheprovisionforbaddebtshasincreasedaccordingly;
21.Impairmentlosseshadayear-on-yearincreaseof4.7512millionyuan,withagrowthrateof571.45%,mainlyduetotheincreaseintheprovisionforinventorydepreciationinthecurrentperiod;
22.Gainondisposalofassetshadayear-on-yearincreaseof6.7387millionyuan,withagrowthrateof1,153.53%,mainlyduetothelossresultingfromleasecancellationincurredbytheimplementationofthenewleasestandardforretailstores;
23.Non-operatingincomehadayear-on-yearincreaseof2.8967millionyuan,withagrowthrateof42.09%,mainlyduetothetransferofaccountspayablethatarenotrequiredtobepaidintonon-operatingincomeduringthecurrentperiod;
24.Non-operatingexpenseshadayear-on-yearincreaseof18.0083millionyuan,withagrowthrateof754.04%,mainlyduetotheprovisionoflitigationcompensationinthecurrentperiod,therewasnosuchmatterinthesameperiodlastyear;
25.Non-controllinginterestshadanincreaseof59.1853millionyuan,withagrowthrateof36.00%,mainlyduetotheacquisitionofnon-wholly-ownedsubsidiariesbythesubsidiaryGuodaDrugStoreduringthecurrentperiod,whichcausedanincreaseintheprofitandlossattributabletominorityshareholdersandanincreaseinthenetprofitofGuodaDrugStoreonayear-on-yearbasis,andtheminorityshareholders'profitandlossattributabletostrategicinvestorWalgreensBootsAlliance(HongKong)InvestmentsLimited(hereinafterreferredtoas"WBA")increasedaccordingly;
26.Othercomprehensiveincome,netoftaxhadayear-on-yearincreaseof0.1439millionyuan,withagrowthrateof100.00%,mainlyduetothechangeofotherequityfromassociatedenterpriseintheperiod;
27.Totalcomprehensiveincomeattributabletonon-controllinginterestshadayear-on-yearincreaseof59.1853millionyuan,withagrowthrateof36.00%,mainlyduetothenewacquisitionofnon-wholly-ownedsubsidiariesbythesubsidiaryGuodaDrugStoreduringthecurrentperiod,whichcausedanincreaseincomprehensiveincome
attributabletominorityshareholdersandanincreaseinthenetprofitofGuodaDrugStoreonayear-on-yearbasis,andthecomprehensiveincomeofminorityshareholdersattributabletoWBAincreasedcorrespondingly;
28.Receiptsoftaxesandsurchargesrefundshadanincreaseof7.2765millionyuanyear-on-year,withagrowthrateof207.42%,mainlyduetotheincreaseintaxrefundsreceivedinthisperiodcomparedwiththesameperiodlastyear;
29.Othercashreceiptsrelatingtooperatingactivitieshadayear-on-yearincreaseof698.8992millionyuan,withagrowthrateof135.09%,mainlyduetothereceiptofspecialreservefundsforthepreventionandcontroloftheCOVID-19outbreak,therewasnosuchmatterinthesameperiodlastyear;
30.Cashpaymentsrelatedtootheroperatingactivitieshadayear-on-yearincreaseof259.1235millionyuan,withagrowthrateof32.11%,mainlyduetotheyear-on-yearincreaseinvariousexpensesandcurrentaccountspaidduringthecurrentperiod;
31.Netcashflowsfromoperatingactivitieshadayear-on-yearincreaseof924.5539millionyuan,withagrowthrateof87.32%,mainlybecausethecompanyhasformulatedstricterfundmanagementplans,increasedthecollectionofaccountsreceivableandeffectivelycontrolledpurchasepayments,andreceivedtheemergencyspecialreservefundsforthepreventionandcontroloftheCOVID-19outbreakinthecurrentperiod;
32.Cashreceiptsfromreturnsofinvestmentshadayear-on-yearincreaseof19.0276millionyuan,withagrowthrateof100.00%,becausereceivedthewithdrawalofprincipalfromtheChinaNationalZhongjinMedicalIndustryFund;
33.Cashreceiptsfromreturnsoninvestmentshadayear-on-yearincreaseof81.3311millionyuan,withagrowthrateof103.95%,becausethecashdividendsreceivedfromassociatesinthecurrentperiodincreasedonayear-on-yearbasis;
34.Cashreceiptsrelatedtootherinvestingactivitieshadayear-on-yeardecreaseof346.5745millionyuan,withagrowthrateof-94.02%,becausetheconsolidatedsubsidiaryPudongNewAreaofShanghaiPharmaceuticalMedicineCo.,Ltd.underthesamecontrolofthesubsidiaryGuodaDrugStoreinthecurrentperiodreceivedthefundsallocatedfromthefundpoolofitsoriginalparentcompanySinopharmGroupCo.,Ltd.inthesameperiodoflastyear,andthefundsoriginallycollectedwastakenbackintothecashpoolinthisperiod;
35.Sub-totalofcashinflowsfrominvestingactivitieshadayear-on-yeardecreaseof245.9187millionyuan,withagrowthrateof-54.43%,mainlybecausetheconsolidatedsubsidiaryPudongNewAreaofShanghaiPharmaceuticalMedicineCo.,Ltd.underthesamecontrolofthesubsidiaryGuodaDrugStoreinthecurrentperiodreceivedthefundsallocatedfromthefundpoolofitsoriginalparentcompanySinopharmGroupCo.,Ltd.
inthesameperiodoflastyear,andthefundsoriginallycollectedwastakenbackintothecashpoolinthisperiod;
36.Cashpaidforacquisitionofinvestmentshadayear-on-yeardecreaseof56.1288millionyuan,withagrowthrateof-66.39%,mainlyduetothedecreaseinthestoretransferfeepaidbythesubsidiaryGuodaDrugStoreforthepurchaseofretailstoresduringthecurrentperiod;
37.Netcashpaidforacquisitionofsubsidiariesandotherbusinessunitshadanayear-on-yearincreaseof2,379.2871millionyuan,withagrowthrateof44,656.29%,mainlyduetothenetcashpaidfortheacquisitionofChengdaFangyuanPharmaceuticalGroupCo.,Ltd.andShanghaiDingqunEnterpriseManagementConsultingCo.,Ltd.bythesubsidiaryGuodaDrugStore,therewasnosuchmatterinthesameperiodlastyear;
38.Cashpaymentsrelatedtootherinvestingactivitieshadayear-on-yeardecreaseof340.7033millionyuan,withagrowthrateof-98.55%,mainlybecausethesubsidiaryGuodaDrugStoremergedintoPudongNewAreaofShanghaiPharmaceuticalMedicineCo.,Ltd.underthesamecontrolduringthecurrentperiod,andthefundpoolinthesameperiodlastyearwascollectedtotheoriginalparentcompanySinopharmGroupCo.,Ltd.,therewasnosuchmatterinthisperiod;
39.Sub-totalofcashoutflowsfrominvestingactivitieshadayear-on-yearincreaseof2,004.8201millionyuan,withagrowthrateof332.98%,mainlyduetothenetcashpaidbythesubsidiaryGuodaDrugStorefortheacquisitionofChengdaFangyuanPharmaceuticalGroupCo.,Ltd.andShanghaiDingqunEnterpriseManagementConsultingCo.,Ltd.inthecurrentperiod,therewasnosuchmatterinthesameperiodlastyear;
40.Netcashflowfrominvestingactivitieshadayear-on-yeardecreaseof2,250.7388millionyuan,withagrowthrateof-1,497.99%,mainlyduetothenetcashpaidbythesubsidiaryGuodaDrugStorefortheacquisitionofChengdaFangyuanPharmaceuticalGroupCo.,Ltd.andShanghaiDingqunEnterpriseManagementConsultingCo.,Ltd.inthecurrentperiod,therewasnosuchmatterinthesameperiodlastyear;
41.Cashproceedsfrominvestmentsbyothershadayear-on-yeardecreaseof44.548millionyuan,withagrowthrateof-100%,mainlyduetothereceiptofcapitalincreasefromminorityshareholdersinthesameperiodlastyear.Therewasnosuchmatterinthisperiod;
42.Cashreceivedfromborrowingshadayear-on-yearincreaseof696.82millionyuan,withagrowthrateof
665.54%,mainlyduetothereceiptofspecialloanfundsforthepreventionandcontroloftheCOVID-19outbreakinthisperiodandtheincreaseinbankloans;
43.Cashreceiptsrelatedtootherfinancingactivitieshadayear-on-yearincreaseof317.677millionyuan,withagrowthrateof16,145.16%,mainlyduetothereceiptofloansfromnon-financialinstitutionsinthecurrentperiodandtheincreaseinthereturnofguaranteedepositsforthedraftreceivedinthecurrentperiod；
44.Sub-totalofcashinflowsfromfinancingactivitieshadayear-on-yearincreaseof969.949millionyuan,withagrowthrateof641.43%,mainlyduetothereceiptofspecialloanfundsforthepreventionandcontroloftheCOVID-19outbreakinthisperiod,andthereceiptofloansfromnon-financialinstitutionsinthisperiod；
45.Cashrepaymentsfordebtshadayear-on-yearincreaseof152.1929millionyuan,withagrowthrateof
94.35%,mainlyduetotheincreaseinloanrepaymentsduringthecurrentperiod;
46.Cashpaymentsrelatedtootherfinancingactivitieshadayear-on-yearincreaseof1,056.3758millionyuan,withagrowthrateof174.70%,mainlyduetotherepaymentofloansfromnon-financialinstitutionsduringthecurrentperiod,andtheincreaseinrentalpaymentsinretailstores;
47.Sub-totalofcashoutflowsfromfinancingactivitieshadayear-on-yearincreaseof1,301.6337millionyuan,withagrowthrateof106.79%,mainlyduetotherepaymentofloansfromnon-financialinstitutionsinthecurrentperiod,andtheincreaseinrentpaidbyretailstores;
48.Netcashflowfromfinancingactivitieshadayear-on-yeardecreaseof331.6847millionyuan,withagrowthrateof-31.07%,mainlyduetotheyear-on-yearincreaseinrentpaidbyretailstores,andtheinvestmentfundspaidbythesubsidiaryGuodaDrugStorefortheconsolidationofthesubsidiaryPudongNewAreaofShanghaiPharmaceuticalMedicineCo.,Ltd.underthesamecontrolinthecurrentperiod;
49.Effectofforeignexchangeratechangesoncashandcashequivalentshadayear-on-yearincreaseof0.1259millionyuan,withagrowthrateof71.52%,mainlyduetotheimpactofexchangeratechanges;
50.Netincreaseincashandcashequivalentshadayear-on-yeardecreaseof1,657.7437millionyuan,withagrowthrateof-1,040.83%,mainlyduetotheinvestmentpaidbythesubsidiaryGuodaDrugStorefortheacquisitionofChengdaFangyuanPharmaceuticalGroupCo.,Ltd.andShanghaiDingqunEnterpriseManagementConsultingCo.,Ltd.duringthecurrentperiod.Therewasnosuchmatterinthesameperiodlastyear.
II.Progressandinfluenceofthemaineventsaswellassolutionanalysisspecification
□Applicable√NotapplicableProgressofsharesbuy-back
□Applicable√NotapplicableImplementationprogressofthereductionofrepurchasessharesbycentralizedbidding
□Applicable√Notapplicable
III.Commitmentsthatthecompany,shareholders,actualcontroller,offeror,directors,supervisors,seniormanagementorotherrelatedpartieshavefulfilledduringthereportingperiodandhavenotyetfulfilledbytheendofreportingperiod
□Applicable√NotapplicableTherearenocommitmentsthatthecompany,shareholders,actualcontroller,offeror,directors,supervisors,seniormanagementorotherrelatedpartieshavefulfilledduringthereportingperiodandhavenotyetfulfilledbytheendofreportingperiod.
IV.Financialassetinvestment
1.Particularaboutsecurityinvestment
□Applicable√NotapplicableTheCompanyhadnosecurityinvestmentinPeriod.
2.Particularsaboutderivativesinvestment
□Applicable√NotapplicableTheCompanyhadnoderivativesinvestmentinPeriod.V.Progressofinvestmentprojectswithraisedfunds
□Applicable√Notapplicable
VI.Predictionof2020businessperformanceEstimationonaccumulativenetprofitfromthebeginningoftheyeartotheendofnextreportperiodtobelossprobablyorthewarningofitsmaterialchangecomparedwiththecorrespondingperiodofthelastyearandexplanationonreason
□Applicable√NotapplicableVII.Majorcontractsfordailyoperations
□Applicable√NotapplicableVIII.Trustfinancing
□Applicable√NotapplicableTheCompanyhadnotrustfinancinginPeriod.IX.Guaranteeoutsideagainsttheregulation
□Applicable√NotapplicableTheCompanyhadnoguaranteeoutsideagainsttheregulationinthereportingperiod.
X.Non-operationalfundoccupationfromcontrollingshareholdersanditsrelatedparty
□Applicable√NotapplicableTheCompanyhadnonon-operationalfundoccupationfromcontrollingshareholdersanditsrelatedparty.XI.Registrationformforreceivingresearch,communicationandinterviewinthereportperiod
□Applicable√NotapplicableTheCompanyhadnoreceivingresearch,communicationorinterviewinthereportperiod.
SectionIV.FinancialStatementI.Financialstatement
1.Consolidatebalancesheet
PreparedbyChinaNationalAccordMedicinesCorporationLtd.
2020-09-30
InRMB
| Item | 2020-9-30 | 2019-12-31 |
| Currentassets: | ||
| Cashandbankbalances | 6,962,649,007.83 | 8,885,729,250.47 |
| Settlementprovisions | ||
| Capitallent | ||
| Tradablefinancialassets | ||
| Derivativefinancialassets | ||
| Notesreceivable | 516,702,799.00 | 793,301,688.64 |
| Accountsreceivable | 16,159,274,568.20 | 10,712,983,544.18 |
| Receivablefinancing | 614,461,184.65 | 446,342,588.46 |
| Advancestosuppliers | 528,161,580.38 | 389,828,785.54 |
| Insurancereceivable | ||
| Reinsurancereceivables | ||
| Contractreserveofreinsurancereceivable | ||
| Otherreceivables | 625,955,680.32 | 501,958,841.43 |
| Including:Interestreceivable | ||
| Dividendreceivable | 834,914.61 | |
| Buyingbackthesaleoffinancialassets | ||
| Inventories | 6,472,039,528.37 | 5,063,274,143.26 |
| Contractualassets | ||
| Assetsheldforsale | ||
| Non-currentassetduewithinoneyear | ||
| Othercurrentassets | 69,483,189.74 | 102,207,498.20 |
| Totalcurrentassets | 31,948,727,538.49 | 26,895,626,340.18 |
| Non-currentassets: | ||
| Loansandpaymentsonbehalf | ||
| Debtinvestment | ||
| Otherdebtinvestment | ||
| Long-termaccountreceivable | ||
| Long-termequityinvestment | 2,180,792,355.94 | 2,105,114,410.88 |
| Otherequityinstrumentsinvestment | 116,021,000.00 | 116,021,000.00 |
| Othernon-currentfinancialassets | 120,972,350.24 | 140,000,000.00 |
| Investmentproperties | 129,386,716.54 | 138,900,358.30 |
| Fixedassets | 830,176,528.72 | 708,000,172.63 |
| Constructioninprogress | 34,002,571.84 | 31,582,575.84 |
| Productivebiologicalasset | ||
| Oilandgasasset | ||
| Right-of-useassets | 2,364,186,871.11 | 1,994,757,862.07 |
| Intangibleassets | 748,672,438.97 | 374,788,799.48 |
| ExpenseonResearchandDevelopment | ||
| Goodwill | 2,746,547,971.28 | 1,010,057,927.17 |
| Long-termprepaidexpenses | 422,329,641.93 | 373,527,968.14 |
| Deferredtaxassets | 98,512,476.79 | 63,110,829.12 |
| Othernon-currentassets | 272,872,270.66 | 77,354,970.39 |
| Totalnon-currentassets | 10,064,473,194.02 | 7,133,216,874.02 |
| Totalassets | 42,013,200,732.51 | 34,028,843,214.20 |
| Currentliabilities: | ||
| Short-termborrowings | 3,223,872,627.85 | 1,453,018,300.01 |
| Loanfromcentralbank | ||
| Capitalborrowed | ||
| Tradingfinancialliability | ||
| Derivativefinancialliability | ||
| Notespayable | 6,517,277,316.76 | 5,555,697,557.53 |
| Accountspayable | 10,192,012,474.51 | 6,703,967,826.54 |
| Accountsreceivedinadvance | ||
| Contractliabilities | 319,872,358.57 | 303,194,940.70 |
| Sellingfinancialassetofrepurchase | ||
| Absorbingdepositandinterbankdeposit | ||
| Securitytradingofagency | ||
| Securitysalesofagency | ||
| Employeebenefitspayable | 297,011,161.64 | 259,640,813.10 |
| Taxpayable | 266,341,378.00 | 253,379,524.34 |
| Otherpayables | 1,819,483,384.19 | 1,822,364,637.62 |
| Including:Interestpayable | 14,054,694.93 | 23,632,632.90 |
| Dividendpayable | 6,389,320.96 | 6,389,320.96 |
| Commissionchargeandcommissionpayable | ||
| Reinsurancepayable | ||
| Liabilityheldforsale | ||
| Non-currentliabilitiesduewithinoneyear | 722,848,572.29 | 611,917,847.37 |
| Othercurrentliabilities | 888,938.88 | 749,710.19 |
| Totalcurrentliabilities | 23,359,608,212.69 | 16,963,931,157.40 |
| Non-currentliabilities: | ||
| Insurancecontractreserve | ||
| Long-termborrowings | 31,633,794.44 | |
| Bondspayable | ||
| Including:Preferredstock | ||
| Perpetualcapitalsecurities | ||
| Leaseliabilities | 1,315,854,064.33 | 1,208,453,029.51 |
| Long-termpayable | 6,938,189.00 | 800,000.00 |
| Long-termemployeebenefitspayable | 1,390,000.00 | 1,433,000.00 |
| Provisions | 67,777,417.09 | |
| Deferredincome | 86,200,079.36 | 88,704,272.88 |
| Deferredtaxliabilities | 208,604,078.87 | 118,284,962.77 |
| Othernon-currentliabilities | 536,417,234.89 | 73,256,514.93 |
| Totalnon-currentliabilities | 2,254,814,857.98 | 1,490,931,780.09 |
| Totalliabilities | 25,614,423,070.67 | 18,454,862,937.49 |
| Owner’sequity: | ||
| Sharecapital | 428,126,983.00 | 428,126,983.00 |
| Otherequityinstrument | ||
| Including:Preferredstock | ||
| Perpetualcapitalsecurities | ||
| Capitalsurplus | 4,372,924,761.28 | 4,470,766,959.44 |
| Less:Inventoryshares | ||
| Othercomprehensiveincome | 46,061,282.19 | 45,917,342.77 |
| Reasonablereserve | ||
| Surplusreserve | 214,063,491.50 | 214,063,491.50 |
| Provisionofgeneralrisk | ||
| Retainedearnings | 8,492,975,215.79 | 7,752,265,659.17 |
| Shareholders’equityattributabletoshareholdersoftheparent | 13,554,151,733.76 | 12,911,140,435.88 |
| Non-controllinginterests | 2,844,625,928.08 | 2,662,839,840.83 |
| Totalshareholders’equity | 16,398,777,661.84 | 15,573,980,276.71 |
| Totalliabilitiesandshareholders’equity | 42,013,200,732.51 | 34,028,843,214.20 |
LegalRepresentative:LinZhaoxiongAccountingPrincipal:GuGuolinAccountingFirm’sPrincipal:WangYing
2.BalanceSheetofParentCompany
InRMB
| Item | 2020-9-30 | 2019-12-31 |
| Currentassets: | ||
| Cashandbankbalances | 3,623,472,432.84 | 2,909,417,289.71 |
| Tradingfinancialassets | ||
| Derivativefinancialassets | ||
| Notesreceivable | 14,900,068.42 | |
| Accountsreceivable | 825,123,171.17 | 571,544,784.65 |
| Receivablefinancing | 14,286,247.98 | 30,194,682.11 |
| Advancestosuppliers | 2,255,341.39 | 7,996,243.28 |
| Otherreceivables | 2,238,224,576.05 | 1,928,941,595.38 |
| Including:Interestreceivable | ||
| Dividendreceivable | 834,914.61 | |
| Inventories | 180,659,951.37 | 169,422,075.78 |
| Contractualassets | ||
| Assetsheldforsale | ||
| Non-currentassetsmaturingwithinoneyear | ||
| Othercurrentassets | 39,482.38 | 39,482.38 |
| Totalcurrentassets | 6,884,061,203.18 | 5,632,456,221.71 |
| Non-currentassets: | ||
| Debtinvestment | ||
| Otherdebtinvestment | ||
| Long-termreceivables | ||
| Long-termequityinvestments | 7,768,347,868.17 | 7,698,756,525.83 |
| Investmentinotherequityinstrument | ||
| Othernon-currentfinancialassets | 120,972,350.24 | 140,000,000.00 |
| Investmentproperties | 1,460,148.67 | 1,484,198.56 |
| Fixedassets | 14,313,510.88 | 14,763,656.62 |
| Constructioninprogress | ||
| Productivebiologicalassets | ||
| Oilandnaturalgasassets | ||
| Right-of-useassets | 5,428,250.46 | 6,217,504.50 |
| Intangibleassets | 4,968,294.45 | 5,838,737.17 |
| Researchanddevelopmentcosts | ||
| Goodwill | ||
| Long-termprepaidexpenses | 4,688,164.95 | 6,130,534.55 |
| Deferredtaxassets | 9,314,310.47 | 9,327,850.53 |
| Othernon-currentassets | 12,442,236.49 | 9,000,000.00 |
| Totalnon-currentassets | 7,941,935,134.78 | 7,891,519,007.76 |
| Totalassets | 14,825,996,337.96 | 13,523,975,229.47 |
| Currentliabilities | ||
| Short-termborrowings | 247,722,171.73 | 121,350,644.36 |
| Tradingfinancialliability |
| Derivativefinancialliability | ||
| Notespayable | 577,672,670.63 | 751,577,900.22 |
| Accountspayable | 604,053,901.91 | 322,436,681.01 |
| Accountsreceivedinadvance | ||
| Contractliabilities | 24,386,087.49 | 7,293,184.46 |
| Employeebenefitspayable | 32,139,686.65 | 30,469,777.88 |
| Taxespayable | 16,082,246.01 | 22,909,124.90 |
| Otherpayables | 2,505,736,963.13 | 2,120,794,765.05 |
| Including:Interestpayable | 358,968.22 | 861,110.53 |
| Dividendpayable | ||
| Liabilityheldforsale | ||
| Non-currentliabilitiesduewithinoneyear | 1,044,745.35 | 32,640,325.77 |
| Othercurrentliabilities | 220,070.94 | 338,196.81 |
| Totalcurrentliabilities | 4,009,058,543.84 | 3,409,810,600.46 |
| Non-currentliabilities: | ||
| Long-termborrowings | 31,633,794.44 | |
| Bondspayable | ||
| Including:preferredstock | ||
| Perpetualcapitalsecurities | ||
| Leaseliabilities | 4,723,839.22 | 5,461,257.38 |
| Long-termpayable | 800,000.00 | 800,000.00 |
| Long-termemployeebenefitspayable | 21,000.00 | |
| Accruedliabilities | ||
| Deferredincome | 939,918.30 | 1,276,698.66 |
| Deferredincometaxliabilities | ||
| Othernon-currentliabilities | 6,750,487.95 | |
| Totalnon-currentliabilities | 44,869,039.91 | 7,537,956.04 |
| Totalliabilities | 4,053,927,583.75 | 3,417,348,556.50 |
| Owners’equity: | ||
| Sharecapital | 428,126,983.00 | 428,126,983.00 |
| Otherequityinstrument | ||
| Including:preferredstock |
| Perpetualcapitalsecurities | ||
| Capitalsurplus | 4,468,412,139.15 | 4,468,385,307.32 |
| Less:Inventoryshares | ||
| Othercomprehensiveincome | 10,573.23 | -133,366.19 |
| Specialreserve | ||
| Surplusreserve | 214,063,491.50 | 214,063,491.50 |
| Retainedearnings | 5,661,455,567.33 | 4,996,184,257.34 |
| Totalowner’sequity | 10,772,068,754.21 | 10,106,626,672.97 |
| Totalliabilitiesandowner’sequity | 14,825,996,337.96 | 13,523,975,229.47 |
3.ConsolidatedProfitStatement(theperiod)
InRMB
| Item | Currentperiod | Lastperiod |
| I.Totaloperatingrevenue | 15,710,564,937.11 | 13,824,236,956.99 |
| Including:Operatingrevenue | 15,710,564,937.11 | 13,824,236,956.99 |
| Interestincome | ||
| Insurancegained | ||
| Commissionchargeandcommissionincome | ||
| II.Totaloperatingcosts | 15,303,846,841.06 | 13,468,651,756.73 |
| Including:Operatingcosts | 13,973,474,907.40 | 12,397,323,704.29 |
| Interestexpense | ||
| Commissionchargeandcommissionexpense | ||
| Cashsurrendervalue | ||
| Netamountofexpenseofcompensation | ||
| Netamountofwithdrawalofinsurancecontractreserve | ||
| Bonusexpenseofguaranteeslip | ||
| Reinsuranceexpense | ||
| Taxandsurcharges | 40,704,486.64 | 36,849,813.53 |
| Sellingexpenses | 1,021,255,859.95 | 789,902,994.19 |
| Administrativeexpense | 247,039,895.13 | 215,510,730.76 |
| R&Dexpense | ||
| Financecosts | 21,371,691.94 | 29,064,513.96 |
| Including:Interestcost | 69,345,341.35 | 73,519,643.35 |
| Interestincome | 47,423,651.34 | 42,782,208.81 |
| Add:otherincomes | 10,332,398.22 | 12,116,753.12 |
| Investmentincome(Lossislistedwith“-”) | 106,744,145.25 | 69,951,393.31 |
| Including:Investmentincomefromassociates | 113,954,215.33 | 86,019,936.49 |
| Incomefromthederecognitionoffinancialassetsmeasuredatamortisedcost(Lossislistedwith“-”) | -7,260,070.08 | -16,118,543.18 |
| Exchangeincome(Lossislistedwith“-”) | ||
| Netexposurehedgingincome(Lossislistedwith“-”) | ||
| Incomefromchangeoffairvalue(Lossislistedwith“-”) | ||
| Creditimpairmentlosses(Lossislistedwith“-”) | -7,503,494.54 | -3,211,918.65 |
| Impairmentlosses(Lossislistedwith“-”) | -3,838,776.90 | -705,879.81 |
| Gainondisposalofassets(Lossislistedwith“-”) | 3,017,582.41 | 613,909.71 |
| III.Operatingprofit(Lossislistedwith“-”) | 515,469,950.49 | 434,349,457.94 |
| Add:Non-operatingincome | 4,558,551.96 | 3,208,143.43 |
| Less:Non-operatingexpenses | 17,387,648.55 | 638,789.06 |
| IV.Totalprofit(Lossislistedwith“-”) | 502,640,853.90 | 436,918,812.31 |
| Less:Incometaxes | 87,693,175.37 | 80,186,257.89 |
| V.Netprofit(Netlossislistedwith“-”) | 414,947,678.53 | 356,732,554.42 |
| (i)Classifybybusinesscontinuity | ||
| 1.profitorlossfromcontinuingoperations(netlosslistedwith‘-”) | 414,947,678.53 | 356,732,554.42 |
| 2.terminationofnetprofit(netlosslistedwith‘-”) | ||
| (ii)Classifybyownership |
| 1.Ownersoftheparent | 354,134,165.83 | 310,253,592.48 |
| 2.Non-controllinginterests | 60,813,512.70 | 46,478,961.94 |
| VI.Othercomprehensiveincome,netoftax | 21,752.53 | |
| Othercomprehensiveincomeattributabletoshareholdersofownersoftheparent,netoftax | 21,752.53 | |
| (I)Othercomprehensiveincomeitemswhichwillnotbereclassifiedsubsequentlytoprofitofloss | ||
| 1.Changesofthedefinedbenefitplansthatre-measured | ||
| 2.Othercomprehensiveincomeunderequitymethodthatcannotbetransfertogain/loss | ||
| 3.Changeoffairvalueofinvestmentinotherequityinstrument | ||
| 4.Fairvaluechangeofenterprise'screditrisk | ||
| 5.Other | ||
| (ii)Othercomprehensiveincomethatmaybereclassifiedtoprofitorloss | 21,752.53 | |
| 1.Othercomprehensiveincomeusingtheequitymethodthatmaybereclassifiedtoprofitorloss | 21,752.53 | |
| 2.Changeoffairvalueofotherdebtinvestment | ||
| 3.Amountoffinancialassetsre-classifytoothercomprehensiveincome | ||
| 4.Creditimpairmentprovisionforotherdebtinvestment | ||
| 5.Cashflowhedgingreserve | ||
| 6.Translationdifferencesarisingontranslationofforeigncurrencyfinancialstatements | ||
| 7.Other | ||
| Netafter-taxofothercomprehensiveincomeattributabletominority |
| shareholders | ||
| VII.Totalcomprehensiveincome | 414,969,431.06 | 356,732,554.42 |
| Totalcomprehensiveincomeattributabletoshareholdersoftheparent | 354,155,918.36 | 310,253,592.48 |
| Totalcomprehensiveincomeattributabletonon-controllinginterests | 60,813,512.70 | 46,478,961.94 |
| VIII.Earningspershare: | ||
| (i)Basicearningspershare | 0.83 | 0.72 |
| (ii)Dilutedearningspershare | 0.83 | 0.72 |
EnterprisecombineunderthesamecontrolinthePeriod,thecombinedpartyrealizednetprofitof0.00Yuanbeforecombination,andrealized-2,559,759.75YuanatlastperiodforcombinedpartyLegalRepresentative:LinZhaoxiongAccountingPrincipal:GuGuolinAccountingFirm’sPrincipal:WangYing
4.ProfitStatementofParentCompany(theperiod)
InRMB
| Item | Currentperiod | Lastperiod |
| I.Operatingrevenue | 1,045,312,749.83 | 1,112,624,846.96 |
| Less:Operatingcost | 998,626,282.80 | 1,064,701,021.03 |
| Taxesandsurcharge | 1,971,974.46 | 1,964,184.59 |
| Salesexpenses | 16,645,559.49 | 17,984,619.36 |
| Administrationexpenses | 21,487,255.62 | 24,299,300.83 |
| R&Dexpenses | ||
| Financecosts | -19,457,068.52 | -12,688,664.89 |
| Including:Interestcost | 12,460,526.51 | 14,404,910.73 |
| Interestincome | 32,385,886.23 | 27,695,670.05 |
| Add:otherincome | 132,260.12 | 219,828.06 |
| Investmentincome(Lossislistedwith“-”) | 113,805,608.42 | 472,311,092.78 |
| Including:Investmentincomefromassociates | 113,923,021.39 | 91,259,842.03 |
| Incomefromthederecognitionoffinancialassetsmeasuredatamortizedcost(Lossis | -117,412.97 | -1,201,462.13 |
| listedwith“-”) | ||
| Netexposurehedgingincome(Lossislistedwith“-”) | ||
| Changingincomeoffairvalue(Lossislistedwith“-”) | ||
| Creditimpairmentlosses(Lossislistedwith“-”) | -161,522.25 | |
| Impairmentloss(Lossislistedwith“-”) | -477,234.68 | -234,019.78 |
| Gainondisposalofassets(Lossislistedwith“-”) | -165.97 | 181,433.34 |
| II.Operatingprofit(Lossislistedwith“-”) | 139,499,213.87 | 488,681,198.19 |
| Add:Non-operatingincome | 237.88 | 373.35 |
| Less:Non-operatingexpense | 0.02 | |
| III.TotalProfit(Lossislistedwith“-”) | 139,499,451.73 | 488,681,571.54 |
| Less:Incometaxes | 6,442,994.33 | 3,675,740.93 |
| IV.Netprofit(Netlossislistedwith“-”) | 133,056,457.40 | 485,005,830.61 |
| (i)profitorlossfromcontinuingoperations(netlosslistedwith‘-”) | 133,056,457.40 | 485,005,830.61 |
| (ii)terminationofnetprofit(netlosslistedwith‘-”) | ||
| V.Othercomprehensiveincome,netoftax | 21,752.53 | |
| (I)Othercomprehensiveincomeitemswhichwillnotbereclassifiedsubsequentlytoprofitofloss | ||
| 1.Changesofthedefinedbenefitplansthatre-measured | ||
| 2.Othercomprehensiveincomeunderequitymethodthatcannotbetransfertogain/loss | ||
| 3.Changeoffairvalueofinvestmentinotherequityinstrument | ||
| 4.Fairvaluechangeofenterprise'screditrisk | ||
| 5.Other | ||
| (II)Othercomprehensiveincome | 21,752.53 |
| thatmaybereclassifiedtoprofitorloss | ||
| 1.Othercomprehensiveincomeusingtheequitymethodthatmaybereclassifiedtoprofitorloss | 21,752.53 | |
| 2.Changeoffairvalueofotherdebtinvestment | ||
| 3.Amountoffinancialassetsre-classifytoothercomprehensiveincome | ||
| 4.Creditimpairmentprovisionforotherdebtinvestment | ||
| 5.Cashflowhedgingreserve | ||
| 6.Translationdifferencesarisingontranslationofforeigncurrencyfinancialstatements | ||
| 7.Other | ||
| VI.Totalcomprehensiveincome | 133,078,209.93 | 485,005,830.61 |
| VII.Earningspershare: | ||
| (i)Basicearningspershare | ||
| (ii)Dilutedearningspershare |
5.ConsolidatedProfitStatement(formtheyear-begintotheperiod-end)
InRMB
| Item | CurrentPeriod | LastPeriod |
| I.Totaloperatingrevenue | 42,880,505,125.63 | 39,423,435,772.29 |
| Including:Operatingrevenue | 42,880,505,125.63 | 39,423,435,772.29 |
| Interestincome | ||
| Insurancegained | ||
| Commissionchargeandcommissionincome | ||
| II.Totaloperatingcosts | 41,581,721,662.96 | 38,242,360,900.06 |
| Including:Operatingcosts | 37,944,504,626.84 | 35,110,200,308.48 |
| Interestexpense | ||
| Commissionchargeandcommissionexpense | ||
| Cashsurrendervalue |
| Netamountofexpenseofcompensation | ||
| Netamountofwithdrawalofinsurancecontractreserve | ||
| Bonusexpenseofguaranteeslip | ||
| Reinsuranceexpense | ||
| Taxandsurcharges | 110,209,795.96 | 99,561,207.90 |
| Sellingexpenses | 2,749,994,678.55 | 2,331,188,042.13 |
| Administrativeexpenses | 690,327,040.05 | 607,359,068.67 |
| R&Dexpense | ||
| Financecosts | 86,685,521.56 | 94,052,272.88 |
| Including:Interestcost | 202,695,852.03 | 208,314,880.76 |
| Interestincome | 112,936,201.56 | 103,423,311.30 |
| Add:otherincome | 46,187,696.54 | 28,607,672.14 |
| Investmentincome(Lossislistedwith“-”) | 211,950,494.51 | 196,824,879.75 |
| Including:Investmentincomefromassociates | 247,559,119.49 | 255,162,226.48 |
| Incomefromthederecognitionoffinancialassetsmeasuredatamortizedcost(Lossislistedwith“-”) | -40,767,172.72 | -58,387,346.73 |
| Exchangeincome(Lossislistedwith“-”) | ||
| Netexposurehedgingincome(Lossislistedwith“-”) | ||
| Incomefromchangeoffairvalue(Lossislistedwith“-”) | ||
| Creditimpairmentlosses(Lossislistedwith“-”) | -29,083,726.06 | -14,646,019.78 |
| Impairmentlosses(Lossislistedwith“-”) | -5,582,665.20 | -831,434.15 |
| Gainondisposalofassets(Lossislistedwith“-”) | 7,322,907.21 | 584,184.27 |
| III.Operatingprofit(Lossislistedwith“-”) | 1,529,578,169.67 | 1,391,614,154.46 |
| Add:Non-operatingincome | 9,778,532.18 | 6,881,835.88 |
| Less:Non-operatingexpense | 20,396,541.07 | 2,388,239.14 |
| IV.Totalprofit(Lossislistedwith“-”) | 1,518,960,160.78 | 1,396,107,751.20 |
| Less:Incometaxes | 297,799,939.72 | 272,310,616.73 |
| V.Netprofit(Netlossislistedwith“-”) | 1,221,160,221.06 | 1,123,797,134.47 |
| (i)Classifybybusinesscontinuity | ||
| 1.profitorlossfromcontinuingoperations(netlosslistedwith‘-”) | 1,221,160,221.06 | 1,123,797,134.47 |
| 2.terminationofnetprofit(netlosslistedwith‘-”) | ||
| (ii)Classifybyownership | ||
| 1.Ownersoftheparent | 997,585,746.42 | 959,408,007.03 |
| 2.Non-controllinginterests | 223,574,474.64 | 164,389,127.44 |
| VI.Othercomprehensiveincome,netoftax | 143,939.42 | |
| Othercomprehensiveincomeattributabletoshareholdersofownersoftheparent,netoftax | 143,939.42 | |
| (I)Othercomprehensiveincomeitemswhichwillnotbereclassifiedsubsequentlytoprofitofloss | ||
| 1.Changesofthedefinedbenefitplansthatre-measured | ||
| 2.Othercomprehensiveincomeunderequitymethodthatcannotbetransfertogain/loss | ||
| 3.Changeoffairvalueofinvestmentinotherequityinstrument | ||
| 4.Fairvaluechangeofenterprise'screditrisk | ||
| 5.Other | ||
| (ii)Othercomprehensiveincomethatmaybereclassifiedtoprofitorloss | 143,939.42 | |
| 1.Othercomprehensiveincomeusingtheequitymethodthatmaybereclassifiedtoprofitorloss | 143,939.42 | |
| 2.Changeoffairvalueofotherdebtinvestment | ||
| 3.Amountoffinancialassetsre-classifytoothercomprehensive |
| income | ||
| 4.Creditimpairmentprovisionforotherdebtinvestment | ||
| 5.Cashflowhedgingreserve | ||
| 6.Translationdifferencesarisingontranslationofforeigncurrencyfinancialstatements | ||
| 7.Other | ||
| Netafter-taxofothercomprehensiveincomeattributabletominorityshareholders | ||
| VII.Totalcomprehensiveincome | 1,221,304,160.48 | 1,123,797,134.47 |
| Totalcomprehensiveincomeattributabletoshareholdersoftheparent | 997,729,685.84 | 959,408,007.03 |
| Totalcomprehensiveincomeattributabletonon-controllinginterests | 223,574,474.64 | 164,389,127.44 |
| VIII.Earningspershare: | ||
| (i)Basicearningspershare | 2.33 | 2.24 |
| (ii)Dilutedearningspershare | 2.33 | 2.24 |
EnterprisecombineunderthesamecontrolinthePeriod,thecombinedpartyrealizednetprofitof0.00Yuanbeforecombination,andrealized-3,587,735.01YuanatlastperiodforcombinedpartyLegalRepresentative:LinZhaoxiongAccountingPrincipal:GuGuolinAccountingFirm’sPrincipal:WangYing
6.ProfitStatementofParentCompany(formtheyear-begintotheperiod-end)
InRMB
| Item | CurrentPeriod | LastPeriod |
| I.Operatingrevenue | 2,817,800,113.39 | 3,120,629,410.26 |
| Less:Operatingcosts | 2,688,190,345.04 | 2,985,973,415.79 |
| Taxesandsurcharge | 4,554,615.32 | 4,483,432.58 |
| Sellingexpenses | 48,021,936.53 | 49,036,664.17 |
| Administrationexpenses | 64,547,735.37 | 62,356,107.14 |
| R&Dexpenses | ||
| Financecosts | -63,295,185.86 | -43,265,784.17 |
| Including:interestexpenses | 34,388,587.85 | 35,792,756.82 |
| Interestincome | 98,955,206.08 | 80,175,392.47 |
| Add:otherincome | 762,181.59 | 552,592.19 |
| Investmentincome(Lossislistedwith“-”) | 863,439,369.20 | 1,078,420,637.97 |
| Including:Investmentincomefromassociates | 247,472,516.77 | 272,540,375.14 |
| Incomefromthederecognitionoffinancialassetsmeasuredatamortisedcost(Lossislistedwith“-”) | -1,644,381.22 | -3,380,337.41 |
| Netexposurehedgingincome(Lossislistedwith“-”) | ||
| Changingincomeoffairvalue(Lossislistedwith“-”) | ||
| Creditimpairmentlosses(Lossislistedwith“-”) | -976,022.96 | -2,527,287.33 |
| Impairmentloss(Lossislistedwith“-”) | -719,966.55 | -336,132.62 |
| Gainondisposalofassets(Lossislistedwith“-”) | -165.97 | 155,358.82 |
| II.Operatingprofit(Lossislistedwith“-”) | 938,286,062.30 | 1,138,310,743.78 |
| Add:Non-operatingincome | 1,834.65 | 46,442.75 |
| Less:Non-operatingexpense | 52,122.74 | |
| III.TotalProfit(Lossislistedwith“-”) | 938,235,774.21 | 1,138,357,186.53 |
| Less:Incometaxes | 16,088,274.42 | 12,674,965.45 |
| IV.Netprofit(Netlossislistedwith“-”) | 922,147,499.79 | 1,125,682,221.08 |
| (i)profitorlossfromcontinuingoperations(netlosslistedwith‘-”) | 922,147,499.79 | 1,125,682,221.08 |
| (ii)terminationofnetprofit(netlosslistedwith‘-”) | ||
| V.Othercomprehensiveincome,netoftax | 143,939.42 | |
| (I)Othercomprehensiveincomeitemswhichwillnotbereclassifiedsubsequentlytoprofitofloss | ||
| 1.Changesofthedefined |
| benefitplansthatre-measured | ||
| 2.Othercomprehensiveincomeunderequitymethodthatcannotbetransfertogain/loss | ||
| 3.Changeoffairvalueofinvestmentinotherequityinstrument | ||
| 4.Fairvaluechangeofenterprise'screditrisk | ||
| 5.Other | ||
| (II)Othercomprehensiveincomethatmaybereclassifiedtoprofitorloss | 143,939.42 | |
| 1.Othercomprehensiveincomeusingtheequitymethodthatmaybereclassifiedtoprofitorloss | 143,939.42 | |
| 2.Changeoffairvalueofotherdebtinvestment | ||
| 3.Amountoffinancialassetsre-classifytoothercomprehensiveincome | ||
| 4.Creditimpairmentprovisionforotherdebtinvestment | ||
| 5.Cashflowhedgingreserve | ||
| 6.Translationdifferencesarisingontranslationofforeigncurrencyfinancialstatements | ||
| 7.Other | ||
| VI.Totalcomprehensiveincome | 922,291,439.21 | 1,125,682,221.08 |
| VII.Earningspershare: | ||
| (i)Basicearningspershare | ||
| (ii)Dilutedearningspershare |
7.ConsolidatedCashFlowStatement(formtheyear-begintotheperiod-end)
InRMB
| Item | CurrentPeriod | LastPeriod |
| I.Cashflowsarisingfromoperatingactivities: | ||
| Cashreceivedfromsalesofgood | 42,418,077,097.10 | 40,055,008,686.20 |
| orrenderingofservices | ||
| Netincreaseofcustomerdepositandinterbankdeposit | ||
| Netincreaseofloanfromcentralbank | ||
| Netincreaseofcapitalborrowedfromotherfinancialinstitution | ||
| Cashreceivedfromoriginalinsurancecontractfee | ||
| Netcashreceivedfromreinsurancebusiness | ||
| Netincreaseofinsuredsavingsandinvestment | ||
| Cashreceivedfrominterest,commissionchargeandcommission | ||
| Netincreaseofcapitalborrowed | ||
| Netincreaseofreturnedbusinesscapital | ||
| Netcashreceivedbyagentsinsaleandpurchaseofsecurities | ||
| Receiptsoftaxesandsurchargesrefunds | 10,784,614.07 | 3,508,074.72 |
| Othercashreceiptsrelatingtooperatingactivities | 1,216,248,037.55 | 517,348,861.84 |
| Sub-totalofcashinflowsfromoperatingactivities | 43,645,109,748.72 | 40,575,865,622.76 |
| Cashpaidforgoodsandservices | 37,533,521,802.87 | 36,077,610,134.36 |
| Netincreaseofcustomerloansandadvances | ||
| Netincreaseofdepositsincentralbankandinterbank | ||
| Cashpaidfororiginalinsurancecontractcompensation | ||
| Netincreaseofcapitallent | ||
| Cashpaidforinterest,commissionchargeandcommission | ||
| Cashpaidforbonusofguaranteeslip | ||
| Cashpaidtoandonbehalfofemployees | 1,913,705,773.98 | 1,672,811,261.76 |
| Cashpaidforalltypesoftaxes | 1,148,433,266.37 | 959,672,684.15 |
| Cashpaymentsrelatedtootheroperatingactivities | 1,066,101,719.26 | 806,978,262.18 |
| Sub-totalofcashoutflowsfromoperatingactivities | 41,661,762,562.48 | 39,517,072,342.45 |
| Netcashflowsfromoperatingactivities | 1,983,347,186.24 | 1,058,793,280.31 |
| II.Cashflowsarisingfrominvestingactivities: | ||
| Cashreceiptsfromreturnsofinvestments | 19,027,649.76 | |
| Cashreceiptsfromreturnsoninvestments | 159,574,046.42 | 78,242,963.78 |
| Netcashreceivedfromdisposaloffixedassets,intangibleassetsandotherlong-termassets | 5,274,705.47 | 4,977,626.76 |
| Netcashreceivedfromdisposalofsubsidiariesandotherunits | ||
| Cashreceiptsrelatedtootherinvestingactivities | 22,040,000.00 | 368,614,498.90 |
| Subtotalofcashinflowfrominvestingactivities | 205,916,401.65 | 451,835,089.44 |
| Cashpaidforacquisitionoffixedassets,intangibleassetsandotherlong-termassets | 188,880,164.05 | 166,514,970.91 |
| Cashpaidforacquisitionofinvestments | 28,410,468.41 | 84,539,317.61 |
| Netincreaseofmortgagedloans | ||
| Netcashpaidforacquisitionofsubsidiariesandotherbusinessunits | 2,384,615,064.76 | 5,328,000.00 |
| Cashpaymentsrelatedtootherinvestingactivities | 5,000,000.00 | 345,703,306.28 |
| Subtotalofcashoutflowfrominvestingactivities | 2,606,905,697.22 | 602,085,594.80 |
| Netcashflowsfrominvestingactivities | -2,400,989,295.57 | -150,250,505.36 |
| III.Cashflowsarisingfromfinancingactivities | ||
| Cashproceedsfrominvestmentsbyothers | 44,548,000.00 | |
| Incl:Cashproceedsfromsubsidiaryinvestmentsbynon-controllingshareholders | 44,548,000.00 | |
| Cashreceivedfromborrowings | 801,520,037.57 | 104,700,000.00 |
| Cashreceiptsrelatedtootherfinancingactivities | 319,644,627.50 | 1,967,629.61 |
| Sub-totalofcashinflowsfromfinancingactivities | 1,121,164,665.07 | 151,215,629.61 |
| Cashrepaymentsfordebts | 313,500,000.00 | 161,307,142.79 |
| Cashpaymentsfordistributionofdividendsorprofitandinterestexpenses | 545,931,923.60 | 452,866,856.35 |
| Incl:Profitanddividendspaidtonon-controllingshareholdersofsubsidiaries | 62,338,791.80 | 28,493,123.11 |
| Cashpaymentsrelatedtootherfinancingactivities | 1,661,056,163.63 | 604,680,365.03 |
| Subtotalofcashoutflowfromfinancingactivities | 2,520,488,087.23 | 1,218,854,364.17 |
| Netcashflowsfromfinancingactivities | -1,399,323,422.16 | -1,067,638,734.56 |
| IV.Effectofforeignexchangeratechangesoncashandcashequivalents | -50,126.70 | -175,994.42 |
| V.Netincreaseofcashandcashequivalents | -1,817,015,658.19 | -159,271,954.03 |
| Add:Cashandcashequivalentsatbeginningoftheyear | 8,426,071,170.16 | 7,634,936,037.30 |
| VI.Cashandcashequivalentsatendofyear | 6,609,055,511.97 | 7,475,664,083.27 |
8.CashFlowStatementofParentCompany(formtheyear-begintotheperiod-end)
InRMB
| Item | Currentperiod | Lastperiod |
| I.Cashflowsarisingfromoperatingactivities: | ||
| Cashreceivedfromsalesofgoodorrenderingofservices | 2,801,262,096.63 | 3,217,890,947.38 |
| Write-backoftaxreceived | ||
| Othercashreceiptsrelatingtooperatingactivities | 118,590,737.66 | 32,674,054.58 |
| Sub-totalofcashinflowsfromoperatingactivities | 2,919,852,834.29 | 3,250,565,001.96 |
| Cashpaidforgoodsandservices | 2,670,157,831.18 | 3,191,926,190.64 |
| Cashpaidtoandonbehalfofemployees | 77,688,934.66 | 73,601,798.69 |
| Cashpaidforalltypesoftaxes | 61,976,566.00 | 43,156,828.71 |
| Cashpaymentsrelatedtootheroperatingactivities | 39,479,023.87 | 24,724,274.57 |
| Sub-totalofcashoutflowsfromoperatingactivities | 2,849,302,355.71 | 3,333,409,092.61 |
| Netcashflowsfromoperatingactivities | 70,550,478.58 | -82,844,090.65 |
| II.Cashflowsarisingfrominvestingactivities: | ||
| Cashreceiptsfromreturnsofinvestments | 32,664,096.76 | |
| Cashreceiptsfromreturnsoninvestments | 333,064,697.85 | 619,976,538.54 |
| Netcashreceivedfromdisposaloffixedassets,intangibleassetsandotherlong-termassets | 2,900.00 | 3,961,383.00 |
| Netcashreceivedfromdisposalofsubsidiariesandotherunits | ||
| Cashreceiptsrelatedtootherinvestingactivities | 1,996,202,038.52 | 1,482,390,000.00 |
| Sub-totalofcashinflowfrominvestingactivities | 2,361,933,733.13 | 2,106,327,921.54 |
| Cashpaidforacquisitionoffixedassets,intangibleassetsandotherlong-termassets | 11,926,875.85 | 6,777,035.03 |
| Cashpaidforacquisitionofinvestments | 19,998,000.00 | |
| Netcashreceivedfromsubsidiariesandotherunitsobtained | ||
| Cashpaymentsrelatedtootherinvestingactivities | 2,296,122,707.02 | 1,812,850,181.28 |
| Sub-totalofcashoutflowsfrominvestingactivities | 2,308,049,582.87 | 1,839,625,216.31 |
| Netcashflowsfrominvestingactivities | 53,884,150.26 | 266,702,705.23 |
| III.Cashflowsarisingfromfinancingactivities | ||
| Cashreceivedfromabsorbinginvestment | ||
| Cashreceivedfromborrowings | 63,864,821.52 | 10,000,000.00 |
| Cashreceiptsrelatedtootherfinancingactivities | 24,518,926,964.22 | 18,437,509,464.22 |
| Sub-totalofcashinflowfromfinancingactivities | 24,582,791,785.74 | 18,447,509,464.22 |
| Cashrepaymentsfordebts | 43,700,000.00 | 10,000,000.00 |
| Cashpaymentsfordistributionofdividends,profitorinterestexpenses | 285,557,151.27 | 191,576,803.94 |
| Cashpaymentsrelatedtootherfinancingactivities | 23,660,780,660.15 | 17,703,057,206.85 |
| Sub-totalofcashoutflowfromfinancingactivities | 23,990,037,811.42 | 17,904,634,010.79 |
| Netcashflowsfromfinancingactivities | 592,753,974.32 | 542,875,453.43 |
| IV.Effectofforeignexchangeratechangesoncashandcashequivalents | -50,126.70 | -175,994.42 |
| V.Netincreaseofcashandcashequivalents | 717,138,476.46 | 726,558,073.59 |
| Add:Cashandcashequivalentsatbeginningoftheyear | 2,894,333,956.38 | 1,817,654,598.01 |
| VI.Cashandcashequivalentsatendofyear | 3,611,472,432.84 | 2,544,212,671.60 |
II.Explanationonfinancialstatementadjustment
1.Financialstatementadjustmentatthebeginningofthefirstyearwhenimplementationofnewrevenuerulesandnewleasingrulesfrom2020
□Applicable√Notapplicable
2.Retrospectiveadjustmentofthecomparativedataforinitialimplementationofnewrevenuerulesandnewleasingrulesfrom2020
□Applicable√NotapplicableIII.AuditreportWhetherthe3
rdquarterlyreporthasbeenauditedornot
□Yes√No3QreportoftheCompanyisunaudited.
ChinaNationalAccordMedicinesCorporationLtd.
Legalrepresentative:LinZhaoxiong
October22,2020